1h Free Analyst Time
The global erythropoietin stimulating agents market is forecasted to grow by USD 5.35 billion during 2025-2030, accelerating at a CAGR of 8.7% during the forecast period. The report on the global erythropoietin stimulating agents market provides a holistic analysis, market size and forecast, trends, growth drivers, and challenges, as well as vendor analysis covering around 25 vendors.Speak directly to the analyst to clarify any post sales queries you may have.
The report offers an up-to-date analysis regarding the current market scenario, the latest trends and drivers, and the overall market environment. The market is driven by escalating burden of chronic kidney diseases, expanding landscape of oncology and chemotherapy induced anemia, proliferation of specialized renal care and dialysis centers.
The study identifies the ascendancy of long-acting formulations and patient centric dosing regimens as one of the prime reasons driving the global erythropoietin stimulating agents market growth during the next few years. Also, maturation of biosimilar sector from entry to ecosystem dominance and paradigm shift toward personalized anemia management and conservative dosing will lead to sizable demand in the market.
The study was conducted using an objective combination of primary and secondary information including inputs from key participants in the industry. The report contains a comprehensive market size data, segment with regional analysis and vendor landscape in addition to an analysis of the key companies. Reports have historic and forecast data.
The global erythropoietin stimulating agents market is segmented as below:
By Type
- Epoetin alfa
- Epoetin beta
- Darbepoetin alfa
- Others
By Indication
- CKD
- Chemotherapy induced anemia
- Perioperative anemia
- Others
By End-User
- Dialysis centers
- Hospitals
- Oncology clinics
- Others
By Region
- North America
- Europe
- Asia
- Rest of World (RoW)
- Rest of World (RoW)
The report covers the following areas:
- Global erythropoietin stimulating agents market sizing
- Global erythropoietin stimulating agents market forecast
- Global erythropoietin stimulating agents market industry analysis
The report presents a detailed picture of the market by the way of study, synthesis, and summation of data from multiple sources by an analysis of key parameters such as profit, pricing, competition, and promotions. It presents various market facets by identifying the key industry influencers. The data presented is comprehensive, reliable, and a result of extensive primary and secondary research. The market research reports provide a complete competitive landscape and an in-depth vendor selection methodology and analysis using qualitative and quantitative research to forecast accurate market growth.
Table of Contents
1 Executive Summary
2 Market Analysis
3 Market Landscape
4 Market Sizing
5 Historic Market Size
6 Qualitative Analysis
7 Five Forces Analysis
8 Market Segmentation by Type
9 Market Segmentation by Indication
10 Market Segmentation by End-user
11 Customer Landscape
12 Geographic Landscape
13 Drivers, Challenges, and Opportunity
14 Competitive Landscape
15 Competitive Analysis
16 Appendix
List of Exhibits
Executive Summary
The following companies are recognized as the key players in the global global erythropoietin stimulating agents market: Akebia Therapeutics, Amgen Inc., Biocon Ltd., Biosidus SA, Dr Reddys Laboratories Ltd., F. Hoffmann La Roche Ltd., GlaxoSmithKline Plc, Intas Pharmaceuticals Ltd., Johnson and Johnson Services, Kyowa Kirin Co. Ltd., LG Chem Ltd., Nanogen Pharmaceuticals, Novartis AG, Pfizer Inc., Reliance Industries Ltd., Sandoz Group AG, STADA Arzneimittel AG, Teva Pharmaceutical Ltd., Zydus Lifesciences Ltd..Commenting on the report, an analyst from the research team said: "The latest trend gaining momentum in the market is ascendancy of long-acting formulations and patient centric dosing regimens."
According to the report, one of the major drivers for this market is the escalating burden of chronic kidney diseases.
The study was conducted using an objective combination of primary and secondary information including inputs from key participants in the industry. The report contains a comprehensive market and vendor landscape in addition to a SWOT analysis of the key vendors.
Companies Mentioned (Partial List)
A selection of companies mentioned in this report includes, but is not limited to:
- Akebia Therapeutics
- Amgen Inc.
- Biocon Ltd.
- Biosidus SA
- Dr Reddys Laboratories Ltd.
- F. Hoffmann La Roche Ltd.
- GlaxoSmithKline PLC
- Intas Pharmaceuticals Ltd.
- Johnson and Johnson Services
- Kyowa Kirin Co. Ltd.
- LG Chem Ltd.
- Nanogen Pharmaceuticals
- Novartis AG
- Pfizer Inc.
- Reliance Industries Ltd.
- Sandoz Group AG
- STADA Arzneimittel AG
- Teva Pharmaceutical Ltd.
- Zydus Lifesciences Ltd.
